Literature DB >> 18451224

PTOV1 expression predicts prostate cancer in men with isolated high-grade prostatic intraepithelial neoplasia in needle biopsy.

Juan Morote1, Sara Fernández, Lide Alaña, Carmela Iglesias, Jacques Planas, Jaume Reventós, Santiago Ramón Y Cajal, Rosanna Paciucci, Inés M de Torres.   

Abstract

PURPOSE: To analyze the expression of PTOV1 in high-grade prostatic intraepithelial neoplasia (HG-PIN) and to explore its usefulness to predict prostate cancer in patients with isolated HG-PIN in needle biopsy (prostate needle biopsy). EXPERIMENTAL
DESIGN: PTOV1 expression in HG-PIN lesions from 140 patients was analyzed by immunohistochemistry in a semiquantitative manner (Histo-score). HG-PIN derived from 79 radical prostatectomies for prostate cancer and from 11 cistoprostatectomies for bladder cancer without prostate cancer were used as positive and negative controls, respectively. Fifty patients with HG-PIN without concomitant cancer at their first prostate needle biopsy were chosen as the study group. Patients were followed by a mean of 2.5 repeated prostate needle biopsies (1-5), during a mean period of 12.4 months (1-39).
RESULTS: PTOV1 expression in HG-PIN from radical prostatectomies showed a significantly higher Histo-score (162.6) compared with specimens from cistoprostatectomies (67.0). In the study group, PTOV1 expression was significantly higher in samples with cancer in the follow-up (11 patients, 22%) compared with samples in which cancer was not detected (151.4 versus 94.6). PTOV1 expression was the only independent predictor of cancer in the multivariate analysis and the area under the curve was 0.803 (95% confidence interval, 0.728-0.878). A threshold of 100 for PTOV1 expression provided 90.9% sensitivity, 51.3% specificity, 34.5% positive predictive value, and 95.2% negative predictive value.
CONCLUSIONS: PTOV1 is overexpressed in HG-PIN associated with cancer and is a potential marker for studying the carcinogenesis and progression of prostate cancer. Prostate needle biopsy with PTOV1 expression in HG-PIN above a threshold of 100 should be repeated immediately for the likely presence of undiagnosed cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18451224     DOI: 10.1158/1078-0432.CCR-07-4987

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  21 in total

1.  PTOV1 is overexpressed in human high-grade malignant tumors.

Authors:  Sara Fernández; Jose L Mosquera; Lide Alaña; Alex Sanchez-Pla; Juan Morote; Santiago Ramón Y Cajal; Jaume Reventós; Inés de Torres; Rosanna Paciucci
Journal:  Virchows Arch       Date:  2010-12-23       Impact factor: 4.064

2.  PTOV1 is associated with UCH-L1 and in response to estrogen stimuli during the mouse oocyte development.

Authors:  Yu-Wei Yao; Yan Shi; Zhe-Fu Jia; Ya-Hong Jiang; Zheng Gu; Jian Wang; Mohamad Aljofan; Zhao-Gui Sun
Journal:  Histochem Cell Biol       Date:  2011-06-16       Impact factor: 4.304

3.  Rapamycin induces Bad phosphorylation in association with its resistance to human lung cancer cells.

Authors:  Yan Liu; Shi-Yong Sun; Taofeek K Owonikoko; Gabriel L Sica; Walter J Curran; Fadlo R Khuri; Xingming Deng
Journal:  Mol Cancer Ther       Date:  2011-11-04       Impact factor: 6.261

4.  Increased PTOV1 expression is related to poor prognosis in epithelial ovarian cancer.

Authors:  Fei Guo; Liu Feng; Ji-Long Hu; Mei-Ling Wang; Peng Luo; Xiao-Ming Zhong; An-Mei Deng
Journal:  Tumour Biol       Date:  2014-10-01

5.  Behavior of the PCA3 gene in the urine of men with high grade prostatic intraepithelial neoplasia.

Authors:  Juan Morote; Marina Rigau; Marta Garcia; Carmen Mir; Carlos Ballesteros; Jacques Planas; Carles X Raventós; José Placer; Inés M de Torres; Jaume Reventós; Andreas Doll
Journal:  World J Urol       Date:  2010-07-07       Impact factor: 4.226

Review 6.  Precursor lesions to prostatic adenocarcinoma.

Authors:  Jonathan I Epstein
Journal:  Virchows Arch       Date:  2008-12-02       Impact factor: 4.064

7.  Prostate tumor overexpressed 1 expression in invasive urothelial carcinoma.

Authors:  Steffen Rausch; Jörg Hennenlotter; Marcus Scharpf; Katharina Teepe; Ursula Kühs; Stefan Aufderklamm; Simone Bier; Johannes Mischinger; Georgios Gakis; Arnulf Stenzl; Christian Schwentner; Tilman Todenhöfer
Journal:  J Cancer Res Clin Oncol       Date:  2016-01-08       Impact factor: 4.553

8.  Immunohistochemical expression of prostate tumour overexpressed 1 (PTOV1) in atypical adenomatous hyperplasia (AAH) of the prostate: additional evidence linking (AAH) to adenocarcinoma.

Authors:  Roberta Mazzucchelli; Marina Scarpelli; Francesca Barbisan; Alfredo Santinelli; Antonio Lopez-Beltran; Liang Cheng; Rodolfo Montironi
Journal:  Cell Oncol (Dordr)       Date:  2012-11-07       Impact factor: 6.730

9.  High-grade prostatic intraepithelial neoplasia.

Authors:  Joseph C Klink; Ranko Miocinovic; Cristina Magi Galluzzi; Eric A Klein
Journal:  Korean J Urol       Date:  2012-05-18

10.  Mcl-1 Interacts with Akt to Promote Lung Cancer Progression.

Authors:  Guo Chen; Dongkyoo Park; Andrew T Magis; Madhusmita Behera; Suresh S Ramalingam; Taofeek K Owonikoko; Gabriel L Sica; Keqiang Ye; Chao Zhang; Zhengjia Chen; Walter J Curran; Xingming Deng
Journal:  Cancer Res       Date:  2019-10-29       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.